SEC Wants $15M From Sanofi Insider Trading Suspect
Law360 (November 10, 2020, 5:13 PM EST) -- The U.S. Securities and Exchange Commission is seeking $14.8 million from a Swiss businessman who has ignored civil and criminal lawsuits accusing him of engaging in insider trading ahead of Sanofi SA's acquisition of Bioverativ Inc.
The federal regulator asked a New York federal judge Monday to enter default judgment against Zurich resident Roland Mathys, equal to three times the $4.9 million he allegedly netted buying more than 1,600 call options for Bioverativ stock in early January 2018 after learning about the pending merger from the son of a senior Sanofi executive.
"Rather than respond to the SEC's amended complaint —...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!